title: Response letter. Effects of linagliptin.
authors.forename: D
authors.initials: D
authors.lastname: Singh-Franco
authors.forename: S
authors.initials: S
authors.lastname: Elrod
authors.forename: C
authors.initials: C
authors.lastname: Harrington
authors.forename: J
authors.initials: J
authors.lastname: McLaughlin-Middlekauff
mesh_terms: D001786:Blood Glucose / Q000187:drug effects*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D005215:Fasting / Q000097:blood; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069476:Linagliptin; D008687:Metformin / Q000627:therapeutic use; D019518:Postprandial Period; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012137:Respiratory System / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects; D015431:Weight Loss / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D000069476:Linagliptin; D008687:Metformin